NORTH CHICAGO, Ill.,
Jan. 11, 2022 /PRNewswire/ -- AbbVie
(NYSE: ABBV) is confirming prior revenue guidance of greater than
$15 billion in combined Rinvoq
(upadacitinib) and Skyrizi (risankizumab) risk-adjusted sales in
2025. AbbVie now expects 2025 risk-adjusted sales of greater than
$7.5 billion for Rinvoq and greater
than $7.5 billion for Skyrizi. The
new Rinvoq sales guidance is the result of lower expected Rinvoq
sales in the U.S. following the recent label updates in approved
indications, partially offset by higher anticipated sales in
international markets, as well as higher anticipated global sales
in Crohn's disease and ulcerative colitis following positive Phase
3 study readouts. The updated Skyrizi sales guidance is based on
continued strong performance in psoriasis.
Forward-Looking Statements and Other Notices
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions, among others,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the failure to
realize the expected benefits of AbbVie's acquisition of Allergan
or to effectively integrate Allergan's business, challenges to
intellectual property, competition from other products,
difficulties inherent in the research and development process,
adverse litigation or government action, and changes to laws and
regulations applicable to our industry. Additional information
about the economic, competitive, governmental, technological and
other factors that may affect AbbVie's operations is set forth in
Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form
10-K, which has been filed with the Securities and Exchange
Commission, as updated by its Quarterly Reports on Form 10-Q and in
other documents that AbbVie subsequently files with the Securities
and Exchange Commission that update, supplement or supersede such
information. AbbVie undertakes no obligation to release publicly
any revisions to forward-looking statements as a result of
subsequent events or developments, except as required by law.
Rinvoq has not been approved by the U.S. Food and Drug
Administration (FDA) for use in atopic dermatitis or ankylosing
spondylitis and AbbVie's regulatory applications for these
indications are currently under review. Rinvoq has not been
approved by the FDA or European Medicines Agency (EMA) for use in
ulcerative colitis, Crohn's disease, or non-radiographic axial
spondyloarthritis. AbbVie's regulatory applications for Rinvoq in
ulcerative colitis and non-radiographic axial spondyloarthritis are
currently under review by the FDA and EMA. Skyrizi has not been
approved by the FDA for use in psoriatic arthritis and AbbVie's
regulatory application for this indication is currently under
review. Skyrizi has not been approved by the FDA or EMA for use in
Crohn's disease or ulcerative colitis. AbbVie's regulatory
applications for Skyrizi in Crohn's disease are currently under
review by the FDA and EMA.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
View original
content:https://www.prnewswire.com/news-releases/abbvie-confirms-guidance-of-greater-than-15-billion-in-combined-risk-adjusted-sales-for-rinvoq-and-skyrizi-in-2025-301457613.html
SOURCE AbbVie